Acadia pharmaceuticals presents daybue™ (trofinetide) real-world evidence and additional data in rett syndrome at the 2024 international rett syndrome foundation (irsf) annual scientific meeting

San diego--(business wire)--acadia pharmaceuticals, inc. (nasdaq: acad) today announced that interim data from the open-label real-world lotus™ study will be presented at the 2024 international rett syndrome foundation (irsf) annual scientific meeting, being held this week in westminster, colorado. lotus is an ongoing, caregiver-reported study evaluating the efficacy and tolerability outcomes in patients with rett syndrome treated with daybue™ (trofinetide). “these interim data from the lotus s.
ACAD Ratings Summary
ACAD Quant Ranking